Hard to say at what point the three platforms would be entertained with BP interests/offers.
I suspect both the OSA and GABAkine programs are still essentially exiting preclinical phase and will need to see a successful human clinical to both garner significant attention and obtain high level valuation of the asset. KRM-ll-81 would likely get grant money to achieve that in human clinicals next year sometime. These 2 assets should hold some significant value currently, but can rise exponentially with human clinical success.
It is curious all the effort surrounding publicizing all the past AMPAkine work. Given they have a phase 2 upcoming and have desired to get an ADHD trial going as well. It all might be a precursor to BP involvement now or more certainly after a successful phase 2 SCI trial.
Meanwhile, back to that awkward silence where everyone is thinking the same thing but only can hear the clock tick tick tick tick tick tick....
Market Data 
Markets 
AI
